Tisagenlecleucel
- Generic Name
- Tisagenlecleucel
- Brand Names
- Kymriah
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1823078-37-0
- Unique Ingredient Identifier
- Q6C9WHR03O
- Background
Tisagenlecleucel is a CD19-directed genetically modified autologous T cell immunotherapy, or a CAR-T cell therapy for B-cell acute lymphoblastic leukemia. It was granted approval by FDA in August 2017 under the market name Kymriah. Tisagenlecleucel is an immunocellular therapy that involves autologous T cells that are collected from each individual patient a...
- Indication
Tisagenlecleucel is indicated for use in individuals aged 25 years and younger with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse.
...
- Associated Conditions
- Refractory Diffuse Large B Cell Lymphoma (DLBCL), Refractory Follicular Lymphoma, Relapsed Diffuse Large B-cell Lymphoma (DLBCL), Relapsed Follicular Lymphoma, Refractory B-cell precursor acute lymphoblastic leukemia, Relapsed B cell precursor Acute lymphoblastic leukemia
- Associated Therapies
- -
Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies
- Conditions
- Interventions
- First Posted Date
- 2024-05-10
- Last Posted Date
- 2024-05-22
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 20
- Registration Number
- NCT06408194
- Locations
- 🇺🇸
Stanford University, Palo Alto, California, United States
A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma
- Conditions
- Interventions
- Biological: TisagenlecleucelDrug: Lenalidomide and rituximab (R2) in 28-day cycles for up to 12 cycles.Drug: Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone or prednisolone (R-CHOP) in 21-day cycles for 6 to 8 cyclesDrug: Lymphodepleting chemotherapyOther: Corticosteroids and/or Radiation (Bridging therapy)
- First Posted Date
- 2023-06-05
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 108
- Registration Number
- NCT05888493
- Locations
- 🇨🇳
Novartis Investigative Site, Taipei, Taiwan
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- Conditions
- Interventions
- Biological: Axicabtagene CiloleucelProcedure: Biospecimen CollectionProcedure: Computed TomographyDrug: CyclophosphamideBiological: MosunetuzumabOther: Patient ObservationDrug: FludarabineDrug: Polatuzumab VedotinBiological: Lisocabtagene MaraleucelProcedure: Positron Emission TomographyBiological: Tisagenlecleucel
- First Posted Date
- 2022-12-01
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 396
- Registration Number
- NCT05633615
- Locations
- 🇺🇸
Highlands Oncology Group - Fayetteville, Fayetteville, Arkansas, United States
🇺🇸Highlands Oncology Group - Rogers, Rogers, Arkansas, United States
🇺🇸Highlands Oncology Group, Springdale, Arkansas, United States
A Second Infusion (Early Reinfusion) of Tisagenlecleucel in Children and Young Adults With B-Cell Acute Lymphoblastic Leukemia(B-ALL)
- Conditions
- Interventions
- First Posted Date
- 2022-07-15
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 33
- Registration Number
- NCT05460533
- Locations
- 🇺🇸
Children's Hospital Colorado (Data Collection Only), Aurora, Colorado, United States
🇺🇸Children's Hospital of Los Angeles (Data Collection Only), Los Angeles, California, United States
🇺🇸Johns Hopkins University (Data Collection Only), Baltimore, Maryland, United States
Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy
- Conditions
- Interventions
- First Posted Date
- 2021-10-13
- Last Posted Date
- 2024-02-22
- Lead Sponsor
- NeoImmuneTech
- Target Recruit Count
- 57
- Registration Number
- NCT05075603
- Locations
- 🇺🇸
Duke Cancer Institute, Durham, North Carolina, United States
🇺🇸City of Hope, Duarte, California, United States
🇺🇸Barbara Ann Karmanos Cancer Hospital dba Karmanos Cancer Center, Detroit, Michigan, United States
Tisagenlecleucel In Primary CNS Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2019-10-22
- Last Posted Date
- 2024-04-16
- Lead Sponsor
- Matthew J. Frigault, M.D.
- Target Recruit Count
- 6
- Registration Number
- NCT04134117
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Efficacy and Safety of Tisagenlecleucel in Adult Patients With Refractory or Relapsed Follicular Lymphoma
- First Posted Date
- 2018-06-26
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 98
- Registration Number
- NCT03568461
- Locations
- 🇺🇸
UCSF Medical Center ., San Francisco, California, United States
🇺🇸City of Hope National Medical Center Dept.ofCityofHopeMedicalCtr1, Duarte, California, United States
🇺🇸Uni of Chi Medi Ctr Hema and Onco, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.